EGFR and head and neck squamous cell carcinoma: Inhibition of EGFR has been examined extensively for the treatment of SCCHN, with previous reports concluding that EGFR is an attractive therapeutic target [12], [13], providing the rationale for the Cetuximab plus RT trial [14].